drugset / Trial / NCT01703819

Explorative Efficacy Profile of Neurexan® in an Experimental Acute Stress Setting in Healthy Subjects

NCT01703819 ↗

Phase 1/2 Completed 66 enrolled Biologische Heilmittel Heel GmbH
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy of acutely dosed Neurexan using an experimental stress test called the Trier Social Stress Test

Timeline

Start
2012-10
Primary completion
2013-04
Completion
2013-04

Outcome

Missed primary endpoint

registry MEDIAN Neurexan®: 3147.4 (247 to 17050) mm*min MEDIAN Placebo: 3022.5 (0 to 21409) mm*min analysis (superiority or other test); Neurexan® vs Placebo; p = 0.5702; ANCOVA NCT01703819 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Neurexan Unknown 0.6 mg —

Indications